GPM Announces Investigation of Sunesis Pharmaceuticals, Inc.
28 July 2015 - 2:00AM
Business Wire
Glancy Prongay & Murray LLP (“GPM”) announces an
investigation on behalf of investors of Sunesis Pharmaceuticals,
Inc. ("Sunesis" or the "Company") (NASDAQ: SNSS). The investigation
concerns whether the Company violated specific sections of the
Securities Exchange Act of 1934 by issuing materially misleading
information to the investing public. Investors who have lost over
$50,000 on their Sunesis investment are encouraged to contact GPM
to discuss their legal rights.
On July 23, 2015, Sunesis announced that the United States Food
and Drug Administration will not approve its blood cancer drug
Qinprezo based on available data, and that the Company must provide
more clinical evidence supporting approval of Qinprezo. On this
news, shares of Sunesis fell $2.25 per share, or more than 70%,
during intraday trading on July 24, 2015. Investors have been
damaged by the alleged fraud of the Company and GPM is preparing a
complaint to seek compensation on behalf of investors.
If you purchased Sunesis shares, have information or would like
to learn more about these claims, or have any questions concerning
this announcement or your rights or interests with respect to these
matters, please contact Casey Sadler of GPM, 1925 Century Park
East, Suite 2100, Los Angeles, California 90067 at 310-201-9150,
Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com,
or visit our website at http://www.glancylaw.com. If you inquire by
email please include your mailing address, telephone number and
number of shares purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150727005859/en/
Glancy Prongay & Murray LLP, Los AngelesCasey Sadler,
310-201-9150 or
888-773-9224shareholders@glancylaw.comwww.glancylaw.com
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Sunesis Pharmaceuticals Inc (NASDAQ): 0 recent articles
More Sunesis Pharmaceuticals, Inc. (MM) News Articles